scholarly article | Q13442814 |
P50 | author | Josep Maria Gatell | Q17030537 |
Agathe León | Q56865082 | ||
Vicens Diaz-Brito | Q56867697 | ||
José Alcamí | Q60617155 | ||
Juan García-Arriaza | Q79782431 | ||
Giuseppe Pantaleo | Q88061163 | ||
José Luis Jiménez | Q95947031 | ||
Beatriz Perdiguero | Q112248161 | ||
Juan Carlos López Bernaldo de Quirós | Q114406508 | ||
Judit Pich | Q114406509 | ||
Joan Albert Arnaiz | Q114406510 | ||
Mariano Esteban | Q30004051 | ||
Mª Ángeles Muñoz-Fernández | Q40088018 | ||
Felipe García | Q41350341 | ||
Carmen E Gómez | Q42100464 | ||
Peter Liljeström | Q55136644 | ||
P2093 | author name string | Jonathan Weber | |
Montserrat Plana | |||
Iñaki Pérez | |||
Amparo Alvarez | |||
Nuria González | |||
Alberto C Guardo | |||
Victoria Jiménez | |||
Matilde Sánchez Conde | |||
María J Maleno | |||
Jose L Nájera | |||
P2860 | cites work | The Spanish HIV BioBank: a model of cooperative HIV research | Q24288934 |
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions | Q27320923 | ||
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine | Q30977303 | ||
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate | Q33749950 | ||
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses | Q34469355 | ||
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects | Q34593969 | ||
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals | Q35844057 | ||
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 | ||
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial | Q36618096 | ||
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara | Q36692389 | ||
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis | Q37413781 | ||
Poxvirus vector-based HIV vaccines | Q37803318 | ||
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c | Q39028785 | ||
A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. | Q39643952 | ||
MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl) | Q40901244 | ||
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates | Q42100401 | ||
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS | Q42575428 | ||
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers | Q44590524 | ||
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. | Q45235855 | ||
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers | Q45423782 | ||
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans | Q45661091 | ||
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone | Q46576663 | ||
Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". | Q53850523 | ||
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. | Q54454033 | ||
P433 | issue | 46 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | HIV/AIDS | Q12199 |
phase I clinical trial | Q5452194 | ||
vector-based vaccine | Q104783588 | ||
P304 | page(s) | 8309-8316 | |
P577 | publication date | 2011-09-09 | |
P1433 | published in | Vaccine | Q7907941 |
P1476 | title | Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) | |
P478 | volume | 29 |